ICI 216,140 (CAS 124001-41-8)

ICI 216,140, a selective antagonist of the angiotensin II type 1 (AT1) receptor, has been extensively studied in scientific research for its role in elucidating the renin-angiotensin system (RAS) and its involvement in cardiovascular physiology. By competitively binding to the AT1 receptor, ICI 216,140 effectively blocks the actions of angiotensin II, a key regulator of blood pressure, vascular tone, and fluid-electrolyte balance. Through detailed investigations, researchers have unveiled the signaling pathways modulated by the AT1 receptor and its implications in hypertension, cardiac hypertrophy, and renal function. Additionally, studies utilizing ICI 216,140 have contributed to our understanding of the physiological and pathophysiological roles of angiotensin II in various organ systems, highlighting its significance in cardiovascular homeostasis. Furthermore, the development and refinement of ICI 216,140 as a research tool have paved the way for exploring novel strategies targeting the renin-angiotensin system for the management of cardiovascular diseases. Overall, ICI 216,140 serves as a valuable pharmacological tool in unraveling the complexities of angiotensin II signaling and its potential implications in cardiovascular research.